Cipla gets USFDA nod for overactive bladder treating drug
Enablex tablets and generic equivalents had US sales of approximately $85 million for the 12 month period ending June 2016
Mumbai: Pharma major Cipla Friday said it has received final approval for its Abbreviated New Drug Application (ANDA) for Darifenacin extended-release tablets from the United States Food and Drug Administration (USFDA).
"We have received final approval for ANDA for Darifenacin extended-release tablets, 7.5 mg and 15mg, from USFDA," a company statement said here.
Darifenacin extended-release tablets are AB-rated generic equivalents of Allergan's Enablex tablets, 7.5 mg and 15 mg, and are a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency.
The product will be launched immediately, the release said.
Enablex tablets and generic equivalents had US sales of approximately $85 million for the 12 month period ending June 2016, according to IMS Health.
Drug firm Cadila Healthcare reported a 52 percent rise in its consolidated net profit to Rs 281.91 crore for the third quarter ended 31 December 2014 on back of robust sales.
According to IMS Health sales data for the 12 months to April 2016, Glenmark said Nystatin and triamcinolone acetonide ointment achieved annual sales of around $37.5 million
As of March 31, 2016, the company has a portfolio of 38 niche ANDA filings in the US, including 16 Para IV filings